Kolexia
Cousin Sophie Oncologie médicale
Cousin Sophie
Oncologie médicale
Institut Bergonié
Bordeaux, France
266 Activités
1.4 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire à petites cellules Sarcomes Carcinome pulmonaire non à petites cellules Carcinomes Tumeurs des tissus mous Thymome Nausée Tumeurs de la thyroïde

Collaborateurs

Voir plus
Italiano Antoine
Italiano Antoine
Institut Bergonié, Bordeaux, France
Toulmonde Maud
Toulmonde Maud
Institut Bergonié, Bordeaux, France
Kind Michele
Kind Michele
Institut Bergonié, Bordeaux, France
Besse Benjamin
Besse Benjamin
Gustave-Roussy, Villejuif, France

Industries

Voir plus
BEIGENE
20 collaboration(s)
Dernière en 2023
Sanofi
20 collaboration(s)
Dernière en 2023
AstraZeneca
10 collaboration(s)
Dernière en 2023
MSD
8 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
Essai Clinique (National Cancer Institute)   21 mars 2024
A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma: An Open-Label, Single Arm, Multicenter Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma
Essai Clinique (Roche)   20 mars 2024
HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON).
Essai Clinique (AstraZeneca)   14 mars 2024
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer: A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib in Refractory Advanced Thymic Carcinoma
Essai Clinique (Dwight Owen)   12 mars 2024
KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma: A Phase 2, Open-Label, Multi-Center Study to Evaluate Efficacy, Safety and Tolerability of KN046 in Subjects With Thymic Carcinoma
Essai Clinique (Jiangsu Alphamab Biopharmaceuticals Co., Ltd)   10 mars 2024
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and in Combination With Trametinib in Subjects With BRAF V600 Mutant Solid Tumors: A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and in Combination With Trametinib in Subjects With BRAF V600 Mutant Solid Tumors
Essai Clinique (C4 Therapeutics, Inc.)   29 février 2024
AcSé: Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
Essai Clinique (Unicancer)   26 février 2024
Impact of metronomic trabectedin combined with low-dose cyclophosphamide on sarcoma microenvironment and correlation with clinical outcome: results from the TARMIC study.
Molecular cancer   19 février 2024
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
Nature medicine   13 février 2024
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024